Lung Cancer Patients Face a Fragmented, Complex Testing Landscape for HER2-Targeted Therapies
NEW YORK – Patients seeking treatment for advanced lung cancer are now evaluated for HER2 alterations via several tests in a fragmented process that can lead to extra biopsies and less-than-optimal treatment plans.
Read more